Solid oral dosage forms of valsartan
Patent 6485745 Issued on November 26, 2002. Estimated Expiration Date: 
August 1, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 1, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3200039 Divisible tablet having controlled and delayed release of the active substance Acyl compounds Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. Readily available konjac glucomannan as a sustained release excipient Use of an angiotensin II antagonist and a benzofuran derivative in the treatment of cardiovascular complaints Patent #: 6218414 InventorsAssigneeApplicationNo. 920159 filed on 08/01/2001US Classes:424/465, With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.)424/464, Tablets, lozenges, or pills424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)514/222.8, Polycyclo ring system having the six-membered hetero ring as one of the cyclos514/223.2, 1,2,4 - Benzothiadiazine - 1,1 - dioxides (including hydrogenated)514/223.5With additional active ingredientExaminersPrimary: Page, Thurman K.Assistant: Di Nola-Baron, Liliana Attorney, Agent or FirmForeign Patent References
International ClassA61K 009/20Foreign Application Priority Data1996-06-27 GBAbstractThe present invention is concerned with solid oral dosage forms of comprisinga) an active agent selected from valsartan and optionally HCTZ , andb) Pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.Other References
Field of SearchWith claimed perfecting feature in contents (e.g., excipient, lubricant, etc.)Tablets, lozenges, or pills Containing polysaccharide (e.g., sugar, etc.) Particulate form (e.g., powders, granules, beads, microcapsules, and pellets) Heterocyclic monomer Polycyclo ring system having the six-membered hetero ring as one of the cyclos With additional active ingredient | |
